Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Reveals Plan To Speed Development Of New COVID-19 Therapies

Project Includes A ‘Therapeutics Booster’ And R&D/Manufacturing Support

Executive Summary

Regulatory flexibilities such as rolling review, conditional marketing authorizations and possibly an EU emergency use authorization will play a key part in the EU’s plans to identify and approve promising new coronavirus treatments.

You may also be interested in...



Lenzilumab & Evusheld Make It Onto EU List Of ‘Most Promising’ COVID-19 Treatments

Two products that were on the European Commission’s original list of the “top five” COVID-19 candidate therapeutics in development have been dropped from the latest “top 10” portfolio.

EU To Boost Portfolio Of Potential COVID-19 Treatments

The European Commission has set up a new expert group on virus variants whose tasks will include selecting the criteria for identifying possible new treatments and vaccines for COVID-19.

May 2021 Update: EU/UK Coronavirus Vaccine And Treatment Progress At A Glance

Rolling reviews are now in progress at the European Medicines Agency for four COVID-19 vaccines and for four potential COVID-19 treatments.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS144284

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel